Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.700 -0.165 (-3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Where Recursion Pharmaceuticals Stands With Analysts
 
Via Benzinga
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
3 Monster Stocks to Hold for the Next 10 Years
A handful of companies are in the right place at the right time with the right product or service. 
Via The Motley Fool
How Is The Market Feeling About Recursion Pharmaceuticals?
 
Via Benzinga
Is Recursion Pharmaceuticals Stock a Buy?
Via The Motley Fool
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
Nvidia-Backed Recursion Pharma Hits 3-Week High, Sparks Retail Buzz Amid Broader AI Hype
The AI chipmaker’s $50 million investment in Recursion, unveiled in 2023 to support AI-driven drug discovery, has been a key driver of investor interest. 
Via Stocktwits
Topics Artificial Intelligence
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025
Via The Motley Fool
Is Recursion Pharmaceuticals Stock a Millionaire Maker?
Via The Motley Fool
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its Workforce
Ark Invest, led by Cathie Wood, made significant trades in 5 companies on Friday: RXRX, ILMN, NTLA, NET, and ADPT. 
Via Benzinga
Topics Workforce
AI Drug Discovery Stocks: Recursion Pharmaceuticals Has A Long Road Ahead
Among the various use-cases for AI, healthcare has been one of the interesting ones. Recursion Pharmaceuticals (RXRX) is one such notable player in the industry that has successfully leveraged AI in... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood's Ark Invest Books Profits On Hot AI Stock Palantir, Sells Bitcoin ETF Shares As BTC Starts 2025 On A Positive Note
On Friday, Cathie Wood-led Ark Invest made significant trades involving PLTR, ARKB, and QSI. The PLTR trade sold shares worth $1.6 million, aligning with Ark's trend of reducing their position in the... 
Via Benzinga
Topics Artificial Intelligence ETFs
Nio, Unity Software And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
1 Artificial Intelligence (AI) Stock That Could Soar in 2025
Via The Motley Fool
Topics Artificial Intelligence
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
What's Going On With Recursion Pharmaceuticals Stock?
Recursion on Tuesday held a webinar to discuss results from the Phase 1/2 study of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. The results were presented at an AACR Special... 
Via Benzinga
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
An Investor's Guide to the Artificial Intelligence (AI) Value Chain
Via The Motley Fool
Topics Artificial Intelligence
Ulta Beauty Posts Upbeat Results, Joins Asana, Lululemon, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Berkshire Hathaway Isn't the Only Publicly Traded Company That Buys Stocks. These 3 Tech Giants Also Have Stock Portfolios.
Via The Motley Fool
Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.